Eleven cases of dermatomyositis accompanied with gynecological malignant tumor: clinical characteristics and short-term follow-up

Eleven cases of dermatomyositis accompanied with gynecological malignant tumor: clinical characteristics and short-term follow-up

Blog Article

Objective: To analyze the clinical characteristics, diagnosis and treatment of dermatomyositis (DM) accompanied with gynecological malignant tumor to provide evidence for early detection and intervention of the disease.Methods: The clinical data of 11 DM patients with gynecological malignant tumor treated in our hospital from 2015 to 2020 were enrolled, and the clinical characteristics and treatment protocols were analyzed.Results: In eleven patients diagnosed DM accompanied with gynecological malignant tumor, three types of cancer were identified, including endometrial cancer (4/11), cervical cancer (2/11), and ovarian cancer (5/11).

Eightout of 11 patients were diagnosed stage Ⅲ-Ⅳ gynecological cancer according to 2020 FIGO(International Federation of Gynecology and Obstetrics) gynecological tumor staging.Ten patients were screened for gynecological cancer by imaging and tumor biomarkers,and diagnosed Built-In Microwave gynecological cancer after being confirmed as DM 1 week to 21 months.The other one patient was found to have ovarian cancer at 21st month after diagnosis of DM because of the increased level of CA12-5 (carbohydrate antigen12-5) during the follow-up, however, her CT imaging of the pelvic and abdominal cavity and tumor biomarkers were normal in initial screening.

The anti-TIF1-γ antibodies in 8 DM patients were tested, and 6 of them were positive.Except one patient with cervical cancer receiving directly radical radiotherapy and chemotherapy, the other 10 patients received gynecological tumor resection.The overall survival rate was 100% during the follow-up of 2 months to 2 years.

There was no tumor recurrence duringthe follow-up, but the DM recurrence appeared in 2patients.Conclusions: For the DM patients lacking signs of malignant tumor in the initial screening, the continuing follow-upand screening for tumor biomarkers should get more attention.The DM patients accompanied gynecological malignant tumor often showed late-stage cancer (Ⅲ-Ⅳ Personal Hygiene staging) and the treatment should be mainly focused on the gynecological tumor.